Literature DB >> 22020080

Multimodal approaches including three-dimensional conformal re-irradiation for recurrent or persistent esophageal cancer: preliminary results.

Shinsaku Yamaguchi1, Takayuki Ohguri, Hajime Imada, Katsuya Yahara, Seung Dae Moon, Aiichiro Higure, Koji Yamaguchi, Ichiro Yoshikawa, Masaru Harada, Yukunori Korogi.   

Abstract

The purpose of this study was to assess the toxicity and efficacy of multimodal approaches, including three-dimensional conformal re-irradiation, for patients with recurrent or persistent esophageal cancer after radiotherapy. Thirty-one patients with esophageal cancer treated with three-dimensional conformal re-irradiation were retrospectively analyzed. Of the 31 patients, 27 patients received concurrent chemotherapy, and 14 patients underwent regional hyperthermia during the re-irradiation. We divided the patients into two groups on the basis of their clinical condition: the curative group (n = 11) or the palliative group (n = 20). Severe toxicities were detected in one patient with Grade 3 esophageal perforation in the curative group, and 5 patients had a Grade 3 or higher toxicity of the esophagus in the palliative group. Advanced T stage at the time of re-irradiation was found to be significantly correlated with Grade 3 or higher toxicity in the esophagus. For the curative group, 10 (91%) of 11 patients had an objective response. For the palliative group, symptom relief was recognized in 8 (57%) of 14 patients with obvious swallowing difficulty. In conclusion, in the curative group with early-stage recurrent or persistent esophageal cancer, the multimodal approaches, including three-dimensional conformal re-irradiation, may be feasible, showing acceptable toxicity and a potential value of promising results, although further evaluations especially for the toxicities of the organs at risk are required. In the palliative group, the benefit of our therapy may be restrictive because severe esophageal toxicities were not uncommon in the patients with advanced T stage at the time of re-irradiation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020080     DOI: 10.1269/jrr.11066

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  8 in total

1.  High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer : Experience from a large single-center cohort.

Authors:  Nils H Nicolay; Johanna Rademacher; Jan Oelmann-Avendano; Jürgen Debus; Peter E Huber; Katja Lindel
Journal:  Strahlenther Onkol       Date:  2016-05-31       Impact factor: 3.621

Review 2.  Heating technology for malignant tumors: a review.

Authors:  H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

3.  Role of upper abdominal reirradiation for gastrointestinal malignancies: a systematic review of cumulative dose, toxicity, and outcomes on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).

Authors:  Luciana Caravatta; Francesco Fiorica; Consuelo Rosa; Luca Boldrini; Anna Rita Alitto; Alessia Nardangeli; Francesco Dionisi; Lavinia Bianco; Fernando Munoz; Marco Lupattelli; Giovanna Mantello; Domenico Genovesi; Mariangela Massaccesi
Journal:  Strahlenther Onkol       Date:  2019-10-04       Impact factor: 3.621

4.  Hyperfractionated radiotherapy for re-irradiation of recurrent esophageal cancer.

Authors:  Kazuya Takeda; Haruo Matsushita; Rei Umezawa; Takaya Yamamoto; Yojiro Ishikawa; Noriyoshi Takahashi; Yu Suzuki; Keiichi Jingu
Journal:  Radiat Oncol J       Date:  2021-09-03

5.  Risk factors of esophageal fistula induced by re-radiotherapy for recurrent esophageal cancer with local primary site.

Authors:  Xinran Wang; Bing Hu; Jinhu Chen; Feihong Xie; Dan Han; Qian Zhao; Hongfu Sun; Chengrui Fu; Chengxin Liu; Zhongtang Wang; Haiqun Lin; Wei Huang
Journal:  BMC Cancer       Date:  2022-02-24       Impact factor: 4.430

6.  Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy.

Authors:  Young Suk Kim; Chang Geol Lee; Kyung Hwan Kim; Taehyung Kim; Joohwan Lee; Yona Cho; Woong Sub Koom
Journal:  Radiat Oncol J       Date:  2012-12-31

7.  Survival benefit of re-irradiation in esophageal Cancer patients with Locoregional recurrence: a propensity score-matched analysis.

Authors:  Liang Hong; Yun-Xia Huang; Qing-Yang Zhuang; Xue-Qing Zhang; Li-Rui Tang; Kai-Xin Du; Xiao-Yi Lin; Bu-Hong Zheng; Shao-Li Cai; Jun-Xin Wu; Jin-Luan Li
Journal:  Radiat Oncol       Date:  2018-09-10       Impact factor: 3.481

8.  Efficacy and toxicity of re-irradiation for esophageal cancer patients with locoregional recurrence: a retrospective analysis.

Authors:  Kaikai Zhao; Youjiao Si; Liangchao Sun; Xiangjiao Meng; Jinming Yu
Journal:  Radiat Oncol       Date:  2020-10-21       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.